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The aim of this study was to evaluate the risk of thrombo-embolic events (TEE) in patients with germ-cell tumours (GCT) who
receive cisplatin-based chemotherapy, to compare this risk to that of a matched control group of non-GCT cancer patients, and
to identify risk factors of TEE. The rate of TEE during the 6 months following the initiation of chemotherapy was assessed in 100
consecutive patients with GCT and in 100 controls with various neoplasms who were matched on sex and age, and who received
first-line cisplatin-based chemotherapy during the same period of time at Institut Gustave Roussy, Villejuif, France. Data were
subsequently tested on a validation group of 77 GCT patients treated in Lyon, France. A total of 19 patients (19%) (95% confidence
interval (CI): 13–28) and six patients (6%) (95% CI: 3–13) had a TEE in the GCT group and the non-GCT control group,
respectively (relative risk (RR): 3.4; Po0.01). Three patients from the GCT group died of pulmonary embolism. In multivariate
analysis, two factors had independent predictive value for TEE: a high body surface area (41.9m
2) (RR: 5 (1.8–13.9)) and an
elevated serum lactate dehydrogenase (LDH) (RR: 6.4 (2.3–18.2)). Patients with no risk factor (n¼26) and those with at least one
risk factor (n¼71) had a probability of having a TEE of 4% (95% CI: 1–19) and 26% (95% CI: 17–37), respectively. In the GCT
validation set, 10 (13%) patients had a TEE; patients with no risk factor and those with at least one risk factor had a probability of
having a TEE of 0 and 17% (95% CI: 10–29), respectively. Patients with GCT are at a higher risk for TEE than patients with non-GCT
cancer while on cisplatin-based chemotherapy. This risk can be accurately predicted by serum LDH and body surface area. This
predictive index may help to study prospectively the impact of thromboprophylaxis in GCT patients.
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The integration of cisplatin-based chemotherapy and surgery in
the first-line treatment of germ-cell tumours (GCT) has resulted in
cure rates of approximately 80% in disseminated cases and more
than 98% when the disease is localised to the testis (Culine et al,
1996; Bosl and Motzer, 1997). The emphasis of clinical trials in the
last 15 years has been to reduce the amount of early and late
toxicity in patients with good-risk GCT. Late complications mainly
include secondary malignancies, bleomycin-induced pulmonary
fibrosis, Raynaud’s phenomenon, peripheral neurotoxicity, infer-
tility, and psychological disorders (Fizazi et al, 2002a). Moreover,
some authors have suggested that there is both an increased
incidence of hypercholesterolaemia (Raghavan et al, 1992) and an
increased cardiovascular risk although this is still a subject of
debate (Doll et al, 1986; Nichols et al, 1992; Gerl, 1994; Huddart
et al, 2003).
Even though the matter of arterial events in GCT survivors
remains controversial, there have been isolated reports on the
occurrence of venous thrombo-embolic events (TEE) in these
patients. However, only a few studies have specifically focused
on this subject (Cantwell et al, 1988; Weijl et al, 2000). It was
originally described by Trousseau that patients with cancer are at
increased risk for venous TEE, although the mechanisms are not
fully elucidated (Trousseau, 1865). These mechanisms may include
procoagulant factors released by tumour cells, tumour-mediated
vascular compression, and secondary immobilisation (Levine et al,
2002). Whether or not the use of chemotherapy increases the
thrombo-embolic risk in cancer patients is still a topic of debate
(Gerl, 1994). The occurrence of acute TEE in young men receiving
chemotherapy for GCT has raised concerns since these complica-
tions may be life threatening and may also be responsible for long-
term complications.
However, there is no definitive evidence that the TEE risk is
increased in patients with GCT compared to other cancer patients.
Therefore, the objectives of this study were to assess the incidence
of TEE in a series of patients with GCT, to compare this incidence
to that of a control population of cancer patients, and to determine
predictive factors for TEE.
Received 29 March 2005; revised 25 July 2005; accepted 2 August 2005;
published online 4 October 2005
*Correspondence: Dr K Fizazi, Department of Medicine, Institut Gustave
Roussy, 39 rue Camille Desmoulins, 94800 Villejuif, France;
E-mail: fizazi@igr.fr
British Journal of Cancer (2005) 93, 909–914
& 2005 Cancer Research UK All rights reserved 0007– 0920/05 $30.00
www.bjcancer.com
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sPATIENTS AND METHODS
Patients
We retrospectively reviewed the incidence of TEE in a population
of 100 consecutive patients with GCT, selected on the following
criteria: male patients, age above 16 years, pathologic evidence
of GCT (seminoma or non-seminoma), a testicular or an
extragonadal primary site and first-line cisplatin-based chemo-
therapy given at Institut Gustave Roussy, Villejuif, France, from
January 1992 to December 1998. Patients with previous chemo-
therapy or radiotherapy were excluded, as well as patients with a
TEE diagnosed before the initiation of chemotherapy.
Thrombo-embolic event was defined as any venous or arterial
thrombo-embolic complication (including superficial thrombo-
phlebitis and thrombophlebitis on venous catheter) occurring
from the first day of chemotherapy to 6 months later. This period
was chosen because cisplatin has been previously associated with
the occurrence of TEE and because this drug has a long-lasting
activity (Schilsky et al, 1982; Gerl and Schierl, 2000). Radiologic
evidence was required to ascertain the diagnosis of TEE and it was
obtained by Doppler ultrasonography, CT scan, arteriography, or
phlebography. The evolution of TEE was extensively studied and
reported with respect to complications, relapse, and long-term
functional sequel.
The incidence of TEE was also assessed in a control population
and compared to that observed in patients with GCT. The control
group consisted of 100 consecutive patients who were matched on
the following criteria: sex, age, pathologic evidence of non-GCT
neoplasm, and first-line cisplatin-based chemotherapy received
at Institut Gustave Roussy during the same period of time. This
control group was taken from an electronic database.
Statistical methods
Patient characteristics were obtained from the charts; they are
expressed as percentages or medians (range). The predictive value
of initial characteristics on the occurrence of a TEE was assessed
using the log-rank test (Peto et al, 1977) for univariate analysis,
and the Cox’s proportional hazards regression model (Cox, 1972)
for multivariate analysis. Factors with predictive value were
combined to build a predictive model. All tests were two sided.
The model was tested on a separate set of 70 patients with GCT
treated at the Centre Le ´on Be ´rard, Lyon, France during the same
period of time (validation set).
RESULTS
Characteristics from the study set of patients with GCT and the
control group of patients with non-GCT malignancies are
summarised in Table 1. Both groups received cisplatin-based
chemotherapy, most often at a dose of 100mgm
 2cycle
 1
(Table 2). Patients from the control group had a large range of
Table 1 Patients characteristics
GCT: study set
(n¼100)
GCT: validation set
(n¼77)
Non-GCT neoplasms: control group
(n¼100)
Median age (range) (years) 30 (16–63) 32 (18–62) 34 (16–63)
Median weight (range) (kg) 73 (47–99) 72 (54–99) 71 (40–99)
Performance status
0 76 (76%) 65 (85%) 78 (78%)
1 17 (17%) 9 (12%) 13 (13%)
2 6 (6%) 2 (3%) 8 (8%)
3 1 (1%) 0 1 (1%)
Smoking history 41/65 (63%) 32/67 (48%) 37/48 (77%)
Histology and tumour site
GCT 86 (86%) 60 (78%)
NSGCT 14 (14%) 17 (22%)
Pure seminoma 86 (86%) 73 (94%)
Testis 14 (14%) 4 (6%)
Extragonadal
Non-GCT
Osteosarcoma 27
Lung cancer 16
Gastrointestinal tract cancer 14
Ewing’s sarcoma 13
Head and neck cancer 12
Others 18
Stage
Stage I 18 (18%) 7 (9%) Localised: 43 (43%)
Stage II 42 (42%) 37 (48%) Metastases: 57 (57%)
Stage III 40 (40%) 33 (43%)
Median maximal tumour diameter (range) (mm) 43 (10–180) 30 (0–150) 68 (4–200)
Prophylactic anticoagulant therapy 12 (12%) 8/76 (11%) 21/96 (22%)
Biology
Abnormal PT 5 (5%) 7/62 (11%) 5 (5%)
Abnormal APTT 5 (5%) 45/72 (63%) 5 (5%)
Elevated fibrinogen 17/22 (77%) 15/24 (63%)
Elevated LDH 41/97 (42%) 20/59 (34%)
GCT¼germ-cell tumours; NSGCT¼nonseminous germ-cell tumours; LDH¼lactate dehydrogenase; PT¼prothrombine time; APTT¼activated partial thromboplastin time.
Thrombosis and germ-cell tumour
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smalignancies and therefore they received a variety of different
chemotherapy regimens. However, all of them received cisplatin-
based chemotherapy; 31% of them received the rapidly recycled
cisplatin, doxorubicin, and ifosfamide (API-AI) regimen (Fizazi
et al, 1997). Patients from the GCT group received cisplatin and
etoposide with or without bleomycin (BEP or EP) (Culine et al,
2003), or cisplatin, doxorubicin, cyclophosphamide alternated
with vinblastine and bleomycin (CISCA-VB regimen) (Fizazi et al,
2002b) (Table 2). Allocation of patients with disseminated GCT to
the IGCCCG prognostic classification (IGCCCG, 1997) was as
follows: good-risk group: 66%; intermediate group: 4%; and poor-
risk group: 30%. Besides tumour origin and chemotherapy, the
two groups were comparable (Table 1). However, patients from the
GCT group were treated less often via a central catheter than
patients from the non-GCT control group (43 vs 74%, P¼0.001).
Criteria for selecting patients for a central venous catheter
included mostly a poor peripheral venous access at examination
and the planned duration of chemotherapy (typically a central vein
catheter was recommended in patients planned to receive more
than three cycles of chemotherapy). Patients from the GCT group
also had more often a disseminated disease than those from the
non-GCT control group (82 vs 57%, P¼0.001). However, this is
balanced by the fact that patients from the non-GCT control group
often had tumour sites well known to be associated with
thrombosis (inferior limb: 35%; pelvis: 14%). The duration of
chemotherapy was comparable (Table 2).
Thrombo-embolic events
Overall, 19 patients (19%) (95% confidence interval (CI): 13–28)
and six patients (6%) (95% CI: 3–13) had a TEE in the GCT group
and the non-GCT control group, respectively (relative risk (RR):
3.4; Po0.01). Initial TEE are described in Table 3. In most cases,
the first TEE occurred during the course of primary chemotherapy.
A second TEE occurred in eight and three patients in the GCT
group and the non-GCT group, respectively (Table 4). Both
patients who initially had a superficial venous thrombosis of the
arm subsequently developed a deep venous thrombosis: throm-
bosis of the leg and pulmonary embolism in the first patient and
lethal pulmonary embolism in the second patient. These two
patients were only receiving a topical anti-inflammatory treatment
for their superficial thrombosis when the deep venous thrombosis
occurred. The other six patients were all receiving anticoagulant
therapy when the second TEE occurred. Overall, two patients from
the GCT group had an arterial TEE and both also had a venous
Table 2 Chemotherapy
Chemotherapy
GCT:
study
group (n¼100)
GCT:
validation
group
(n¼77)
Non-GCT
neoplasms:
control
group
(n¼100)
Regimen
BEP 46 (46%) 46 (60%)
EP 42 (42%) 28 (36%)
CISCA-VB 12 (12%) 3 (4%)
API-AI 31 (31%)
Drugs
Cisplatin 100 (100%) 77 (100%) 100 (100%)
Etoposide 88 (88%) 74 (96%) 11 (11%)
Bleomycin 58 (58%) 49 (63%) 4 (4%)
Doxorubicin 12 (12%) 3 (4%) 31 (31%)
Cyclophosphamide 12 (12%) 3 (4%) 1 (1%)
Vinblastine 12 (12%) 3 (4%) 5 (5%)
Ifosfamide 36 (36%)
Epirubicine 11 (11%)
Vinorelbine 8 (8%)
5-Fluorouracil 7 (7%)
a-Interferon 2 (2%)
Thiotepa 1 (1%)
Docetaxel 1 (1%)
Interleukin-2 1 (1%)
Mitomycin C 1 (1%)
Duration of chemotherapy (days) 63 (6–408) 68 (4–129) 51 (3–258)
Neutropenic fever 19 (19%) 24 (33%) 16 (16%)
Postchemotherapy surgery 39 (39%) 40 (52%) 39 (39%)
CGT¼germ-cell tumours.
Table 3 First TEE
GCT:
study
group
(n¼100)
GCT:
validation
group
(n¼77)
Non-GCT
neoplasms:
control group
(n¼100)
Patients with a first TEE 19 10 6
Timing of the first TEE
During chemotherapy 14 7 4
After the end of chemotherapy 5 3 2
Deep venous thrombosis 16 9 6
Leg 6 3
Arm 4 1
Inferior vena cava 4 1 5
Superior vena cava 1 1
Pulmonary embolism 1 2
Renal vein 1 1
Superficial venous thrombosis 2
a 1
a 0
Arterial thrombosis 10 0
Stroke 1
aAll these patients subsequently developed a deep venous thrombosis. GCT¼germ-
cell tumours; TEE¼thrombo-embolic events; PT¼prothrombine time;
.APTT¼activated partial thromboplastin time.
Table 4 Complications of TEE
GCT:
study group
(n¼19
first TEE)
GCT:
validation
group
(n¼10
first TEE)
Non-GCT
neoplasms:
control group
(n¼6 first TEE)
Relapse of TEE 8
a 1
a 3
a
Venous
Pulmonary embolism 7 2
Leg 1 1 1
Arm 2
Inferior vena cava 1
Arterial
Acute ischaemia of the leg 1
Long-term sequels 6
b 3
b 3
b
Oedema of the leg 4 2 2
Peripheral venous
circulation or dermitis
21
Chronic pain 2
Walking limitation 1
Renal failure 1
Death 3 0 0
aSome patients had multiple sites of second TEE.
bSome patients had multiple
sequels. TEE¼thrombo-embolic events; GCT¼germ-cell tumours.
Thrombosis and germ-cell tumour
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sTEE: in the first patient, a lethal pulmonary embolism occurred
6 weeks after a stroke, and in the second patient, a venous
thrombosis of the superior cava vena related to a central catheter
was followed 10 days later by an acute ischaemia of the leg (no
long-term sequel after arterial thrombectomy).
Long-term complications occurred in six and three patients in
the two groups, respectively. Three patients from the GCT group
died of pulmonary embolism (one of them having also a stroke).
Univariate analysis
A number of parameters were tested in univariate analysis to
assess whether they were predictors of a first TEE in the GCT
group (Table 5). Six parameters had a significant predictive value
for TEE: age 430 years, a histology of pure seminoma, weight
470kg, body surface area 41.9m
2, elevated serum lactate
dehydrogenase (LDH), and elevated serum alkaline phosphatase.
Multivariate analysis
Predictive factors of TEE identified in univariate analysis were
tested in multivariate analysis using the Cox model. Two models
were built by entering either weight or body surface area in the
analysis. Results are summarised in Table 6. In the first model, two
factors had independent predictive value for TEE: a high body
surface area (41.9m
2) and an elevated serum LDH. In the second
model, weight over 70kg and an elevated serum LDH were
independent predictors of TEE.
The first model was used to build a risk index for TEE: patients
with no risk factor (body surface area p1.9m
2 and normal serum
LDH; n¼26) and those with at least one risk factor (n¼71) had a
probability of having a TEE of 4% (95% CI: 1–19) and 26% (95%
CI: 17–37), respectively.
Validation set
To validate these data, a separate set of 70 patients with GCT
treated at the Centre Le ´on Be ´rard, Lyon, France, during the same
period of time was analysed. Their characteristics are summarised
in Tables 1 and 2. Patient characteristics were similar in the study
set and the validation set. Overall, 10 (13%) of patients from the
validation set had a TEE in the first 6 months following the start of
chemotherapy (Tables 3 and 4). The only patient with a superficial
venous thrombosis subsequently developed a deep venous
thrombosis (leg and inferior vena cava).
Independent predictive factors of TEE identified in the study set
were tested in this validation population: elevated serum LDH and
a high body surface area were associated with a relative risk of
TEE of 4.6 (95% CI: 0.6–37.9) and 1.7 (95% CI: 0.4–7.1) respectively.
When the risk index of TEE was tested in this population, patients
with no risk factor (body surface area p1.9m
2 and a normal
serum LDH; n¼16) and those with at least one risk factor (n¼60)
had a probability of having a TEE of 0 and 17% (95% CI: 10–29),
respectively.
DISCUSSION
In this study, we provide evidence for the first time that patients
with GCT who receive cisplatin-based chemotherapy are at a
significantly higher risk of having a thrombosis in the subsequent
6 months compared with those with other cancers who received
similar treatments. Moreover, the risk of having a thrombosis
could be predicted in GCT patients using two simple factors: a high
body surface area (41.9m
2) (or a high weight) and an elevated
serum LDH before chemotherapy. Patients with no risk factor had
a risk of thrombosis of 4% while those with at least one risk factor
had a risk of 26%. These features were 0 and 17% respectively in a
validation set of patients with GCT treated in a different
institution. Morbidity and mortality were relevant in this
population of young men who are likely to achieve a cure of their
Table 5 Univariate analysis of predictive factors for TEE in patients with
GCT
Characteristics Number of TEE P Relative risk
Age (years)
p30 3 0.001 1
430 16 6.8
Weight (kg)
p70 3 0.002 1
470 16 5.5
Body surface area (m
2)
p1.9 5 0.01 1
41.9 14 3.4
Performance status (WHO)
0–1 17 0.31
2–3 2
Histology
Pure seminoma 6 0.01 3.4
NSGCT 13 1
Primary tumour site
Testis 16 0.7
Extragonadal 3
IGCCCG classification
Good 10 0.36
Intermediate or poor 7
Stage before chemotherapy
Stage I 2 0.63
Stage II 9
Stage III 8
Maximal tumour diameter (mm)
p40 4 0.15
440 8
Central venous catheter
Yes 11 0.14
No 8
Febrile neutropenia
Yes 6 0.09 2.2
No 13 1
Preventive anticoagulant therapy
Yes 4 0.15
No 15
Alkaline phosphatase
Normal 16 0.00001 1
Elevated 3 14.5
PT, APTT
Norma 13 0.08 1
Abnormal 6 2.3
LDH
Normal 5 0.01 1
Elevated 14 4.6
NSGCT¼nonseminous germ-cell tumours; TEE¼thrombo-embolic events;
LDH¼lactate dehydrogenase; PT¼prothrombine time; APTT¼activated partial
thromboplastin time.
Thrombosis and germ-cell tumour
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scancer. TEE consisted mainly in venous thrombosis, with arterial
events being more rare.
A large number of TEE occurring in GCT patients have been
published as case reports (Doehn et al, 2000; Koga et al, 2001;
Blokh et al, 2003; Leslie et al, 2003; cases published before 2000
reviewed in Weijl et al, 2000). In a British series of 333 patients
with advanced GCT, the incidence of vena cava compression was
9.3%, of whom 29% had a thrombo-embolic complication and
one patient died of pulmonary embolism (Hassan et al, 1999). Two
previous studies also underscored the apparent high risk of TEE in
GCT patients receiving chemotherapy, although there was no
control group in these studies (Cantwell et al, 1988; Weijl et al,
2000). In a series of 52 patients, Cantwell et al (1988) reported 10
TEE (19%), including seven venous events, three arterial events,
and one death. In another series of 179 patients, Weijl et al (2000)
reported 15 TEE (8%), including 13 venous events, two arterial
events, and one death. Moreover, a recent study with a 10-year
follow-up showed that GCT survivors are at a higher cardiac risk
than controls in the long term (Huddart et al, 2003). Therefore,
based on our experience and previous publication, there is
evidence that GCT patients have a three-fold higher risk of TEE
(consisting mostly in venous events) during chemotherapy and
soon afterwards, and that they have a two-fold higher risk of
cardiac events in the long term.
The pathogenesis of TEE in GCT patients is not fully under-
stood. Whether the causes are cancer related, treatment related, or
both is still unknown. One weakness of our study was the relatively
high number of parameters that were tested in univariate analysis
compared to the limited number of patients (100). In the Weijl
series, liver metastases and high doses of steroids (used as anti-
emetics) were independent predictors of TEE, but these factors
were not tested in a separate set of GCT patients (Weijl et al, 2000).
In our study, the fact that CGT patients had a much higher risk for
TEE than non-GCT cancer patients, even though both received
cisplatin-based chemotherapy, indicates that cisplatin itself is not
the only risk factor for TEE, in contrast with previous hypothesis
(Icli et al, 1993). However, we can certainly not rule out a direct
or indirect role of chemotherapy in the pathogenesis of TEE.
Other drugs, in particular bleomycin (Schwarzer et al, 1991) and
etoposide (Schwarzer et al, 1991; Airey et al, 1995), as well as the
traditional 5-day protocols used in GCT might favour the
occurrence of TEE, either via immobilisation or the daily use of
steroids. A high body surface area (or weight) was identified as
a risk factor of TEE in our study. This may be due to a direct
effect since obesity is a well-known risk factor of venous TEE
(Rosendaal, 1999). Alternatively, it may be due to an indirect factor
related to chemotherapy since doses of chemotherapy drugs
(except for bleomycin) are prescribed according to body surface
area. Interestingly, hypercholesterolaemia has been suggested to be
found more often in GCT survivors (Gietema et al, 1992; Raghavan
et al, 1992; Meinardi et al, 2000) and this may be a potential
explanation for arterial TEE during chemotherapy for GCT. In
contrast, a recent study did not find any correlation between
cisplatin administration and lipid profile in GCT survivors (Fenton
et al, 2002).
Apart from the potential involvement of treatment-related
factors, there is some evidence to support a direct contribution
of GCT to the occurrence of TEE. For example, Weijl et al (2000)
reported that a number of GCT patients experienced a TEE even
though they had not received anticancer treatment. Indeed, we
have made similar observations. Moreover, human teratocarcinoma
cell lines release plasma membrane vesicles with procoagulant
properties (Dvorak et al, 1983). Serum LDH is linked with tumour
bulk and prognosis in advanced GCT (Fossa et al, 1997; IGCCCG,
1997) and we show in this study that this factor also predicts the
risk of TEE. These findings indirectly support the role of GCT in
the occurrence of TEE. Whether the secretion of LDH by GCT cells
has a direct effect or is associated with the production of
procoagulant factors is unknown.
In our opinion, the high incidence of TEE in GCT patients with
either a high body surface area, a high serum LDH, or both, and
who receive cisplatin-based chemotherapy is sufficient justification
to prospectively evaluate the potential impact of thromboprophy-
laxis in these patients. However, this strategy needs to be
cautiously balanced with the potential risk of thrombocytopenia
(although usually mild) related to chemotherapy in patients with
GCT. Recently, large studies have demonstrated that subcutaneous
low-molecular-weight heparin can be safely used and reduces the
risk of TEE in patients with acute medical illnesses (Samama et al,
1999). Moreover, recent randomised trials have suggested that low-
molecular-weight heparin may be safer than vitamin K antagonists
and that they may also be better in reducing the risk of TEE
recurrence in cancer patients (Meyer et al, 2002; Lee et al, 2003,
2005).
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